Myocardial Infarction with Nonobstructive Coronary ArteriesMINOCA
Conditions
Interventions
A (Experimental Group):Take Musk Tongxin Drop Pill+Standardized diagnosis and treatment (statins, dual antiplatelet therapy, beta-blockers, ACE inhibitors/ARBs, etc.)
B (Control Group):Take a placebo+Standardized diagnosis and treatment (statins, dual antiplatelet therapy, beta-blockers, ACE inhibitors/ARBs, etc.)
Sponsors
Zhongda Hospital Affiliated to Southeast University
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1) Participants aged =18 years. 2) Subjects with suspected MINOCA (defined as: i) acute myocardial infarction; ii) CAG showing no evidence of obstructive coronary artery disease [i.e. no coronary stenosis >50%]; iii) no specific alternative diagnosis based on clinical presentation). 3) Subjects are able to verbally confirm their understanding and acceptance of the risks benefits and treatment plan of invasive physiological or imaging assessment and he/she or his/her legally authorized representative provides written informed consent prior to any study-related procedures. 4) Patients eligible for coronary angiography assessment.
Exclusion criteria
Exclusion criteria: 1) Patients are allergic to or have contraindications for any of the following medications: heparin aspirin clopidogrel prasugrel ticagrelor or contrast agents (patients with documented sensitivity to contrast agents may be enrolled if they can be effectively pre-treated with steroids and diphenhydramine [e.g. for rash]). 2) Patients with active pathological bleeding or major bleeding in the gastrointestinal or genitourinary system within the past 3 months. 3) Patients with a history of bleeding or known coagulopathy (including heparin-induced thrombocytopenia). 4) Patients who have taken Musk Tongxin Drop Pill within four weeks prior to randomization. 5) Pregnant or breastfeeding women or patients planning to become pregnant during the study period. 6) Patients with comorbidities and an expected survival of less than one year. 7) Patients who are currently participating in other clinical studies.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Seattle Angina Questionnaire; | — |
Secondary
| Measure | Time frame |
|---|---|
| Composite endpoint of rehospitalization for myocardial infarction, stroke (including ischemic and hemorrhagic stroke), heart failure, or repeat coronary angiography;myocardial infarction;The functional and morphological characteristics of cardiac magnetic resonance;Readmission for heart failure;Coronary angiography;Stroke (including ischemic and hemorrhagic stroke);Mortality rate at 12 months; | — |
Countries
China
Contacts
Public ContactGenshan Ma
Zhongda Hospital Affiliated to Southeast University
Outcome results
None listed